PPARG: A Promising Therapeutic Target in Breast Cancer and Regulation by Natural Drugs

Table 2

PPARG expression levels in ER+ and ER− BC patients in relation to clinicopathological characteristics.

		Clinicopathological characteristics	High expression group	Low expression group	-Value
Status	ER+	Alive	364	343	0.041
		Dead	40	60
	ER−	Alive	97	99	0.754
		Dead	22	19
Age	ER+	Mean (SD)	58.2 (13)	60.5 (13.5)	0.015
		Median [Min, Max]	58 [26, 90]	61 [29, 90]
	ER−	Mean (SD)	56.1 (11.8)	55.7 (12.9)	0.789
		Median [Min, Max]	55 [29, 85]	54.5 [26, 90]
Gender	ER+	Female	399	396	0.768
		Male	5	7
	ER−	Female	119	118	≤0.001
		Male	0	0
pT-stage	ER+	TX	0	2	0.025
		T1	123	90
		T2	207	247
		T3	65	47
		T4	9	17
	ER−	TX	0	1	0.982
		T1	29	25
		T2	72	77
		T3	13	10
		T4	5	5
pN-stage	ER+	NX	6	10	0.182
		N0	181	175
		N1	139	146
		N2	39	51
		N3	39	21
	ER−	NX	1	1	0.375
		N0	61	75
		N1	32	30
		N2	15	7
		N3	10	5
pM-stage	ER+	MX	67	70	0.553
		M0	329	320
		M1	6	10
	ER−	MX	15	10	0.571
		M0	101	106
		M1	2	2
pTNM-stage	ER+	X	4	7	0.013
		I	81	60
		II	211	231
		III	100	92
		IV	6	9
	ER−	X	0	1	0.292
		I	19	16
		II	65	82
		III	31	15
		IV	1	2